1. The Influence of Cannabinoids on Generic Traits of Neurodegeneration.
Fagan SG, Campbell VA.
Br J Pharmacol. 2013 Oct 31. doi: 10.1111/bph.12492. [Epub ahead of print] PMID: 24172185 [PubMed – as supplied by publisher] Related citations
2. Oleoylethanolamide reduces L-DOPA-induced dyskinesia via TRPV1 receptor in a mouse model of Parkinson´s disease.
González-Aparicio R, Moratalla R.
Neurobiol Dis. 2013 Oct 17;62C:416-425. doi: 10.1016/j.nbd.2013.10.008. [Epub ahead of print] PMID: 24140894 [PubMed – as supplied by publisher] Related citations
3. Cannabinoid modulation of neuroinflammatory disorders.
Saito VM, Rezende RM, Teixeira AL.
Curr Neuropharmacol. 2012 Jun;10(2):159-66. doi: 10.2174/157015912800604515.
PMID: 23204985 [PubMed] Free PMC Article
Related citations
4. Pain in neurological conditions.
Nandi PR.
Curr Opin Support Palliat Care. 2012 Jun;6(2):194-200. doi: 10.1097/SPC.0b013e328352edff. Review.
PMID: 22498834 [PubMed – indexed for MEDLINE] Related citations
5. New agents promote neuroprotection in Parkinson’s disease models.
Santos CM.
CNS Neurol Disord Drug Targets. 2012 Jun 1;11(4):410-8. Review.
PMID: 22483311 [PubMed – indexed for MEDLINE] Related citations
6. The decrease of dopamine D₂/D₃ receptor densities in the putamen and nucleus caudatus goes parallel with maintained levels of CB₁ cannabinoid receptors in Parkinson’s disease: a preliminary autoradiographic study with the selective dopamine D₂/D₃ antagonist [³H]raclopride and the novel CB₁ inverse agonist [¹²⁵I]SD7015.
Farkas S, Nagy K, Jia Z, Harkany T, Palkovits M, Donohou SR, Pike VW, Halldin C, Máthé D, Csiba L, Gulyás B.
Brain Res Bull. 2012 Apr 10;87(6):504-10. doi: 10.1016/j.brainresbull.2012.02.012. Epub 2012 Mar 7.
PMID: 22421165 [PubMed – indexed for MEDLINE] Related citations
7. Δ⁹-tetrahydrocannabinol (Δ⁹-THC) exerts a direct neuroprotective effect in a human cell culture model of Parkinson’s disease.
Carroll CB, Zeissler ML, Hanemann CO, Zajicek JP.
Neuropathol Appl Neurobiol. 2012 Oct;38(6):535-47. doi: 10.1111/j.1365-2990.2011.01248.x.
PMID: 22236282 [PubMed – indexed for MEDLINE] Related citations
8. The cannabinoid agonist WIN55212-2 decreases L-DOPA-induced PKA activation and dyskinetic behavior in 6-OHDA-treated rats.
Martinez A, Macheda T, Morgese MG, Trabace L, Giuffrida A.
Neurosci Res. 2012 Mar;72(3):236-42. doi: 10.1016/j.neures.2011.12.006. Epub 2011 Dec 17.
PMID: 22192465 [PubMed – indexed for MEDLINE] Free PMC Article
Related citations
9. Therapeutic potential of cannabinoids in the treatment of neuroinflammation associated with Parkinson’s disease.
Little JP, Villanueva EB, Klegeris A.
Mini Rev Med Chem. 2011 Jun;11(7):582-90. Review.
PMID: 21699489 [PubMed – indexed for MEDLINE] Related citations
10. Symptom-relieving and neuroprotective effects of the phytocannabinoid Δ⁹-THCV in animal models of Parkinson’s disease.
García C, Palomo-Garo C, García-Arencibia M, Ramos J, Pertwee R, Fernández-Ruiz J.
Br J Pharmacol. 2011 Aug;163(7):1495-506. doi: 10.1111/j.1476-5381.2011.01278.x.
PMID: 21323909 [PubMed – indexed for MEDLINE] Free PMC Article
Related citations
11. The distinct role of medium spiny neurons and cholinergic interneurons in the D₂/A₂A receptor interaction in the striatum: implications for Parkinson’s disease.
Tozzi A, de Iure A, Di Filippo M, Tantucci M, Costa C, Borsini F, Ghiglieri V, Giampà C, Fusco FR, Picconi B, Calabresi P.
J Neurosci. 2011 Feb 2;31(5):1850-62. doi: 10.1523/JNEUROSCI.4082-10.2011.
PMID: 21289195 [PubMed – indexed for MEDLINE] Free Article
Related citations
12. The multiplicity of action of cannabinoids: implications for treating neurodegeneration.
Gowran A, Noonan J, Campbell VA.
CNS Neurosci Ther. 2011 Dec;17(6):637-44. doi: 10.1111/j.1755-5949.2010.00195.x. Epub 2010 Sep 28. Review.
PMID: 20875047 [PubMed – indexed for MEDLINE] Related citations
13. Cannabinoids and Parkinson’s disease.
García-Arencibia M, García C, Fernández-Ruiz J.
CNS Neurol Disord Drug Targets. 2009 Dec;8(6):432-9. Review.
PMID: 19839934 [PubMed – indexed for MEDLINE] Related citations
14. In vivo pharmacology of endocannabinoids and their metabolic inhibitors: therapeutic implications in Parkinson’s disease and abuse liability.
Giuffrida A, McMahon LR.
Prostaglandins Other Lipid Mediat. 2010 Apr;91(3-4):90-103. doi: 10.1016/j.prostaglandins.2009.05.004. Epub 2009 Jun 10. Review.
PMID: 19523530 [PubMed – indexed for MEDLINE] Free PMC Article
Related citations
15. WIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson’s disease.
Price DA, Martinez AA, Seillier A, Koek W, Acosta Y, Fernandez E, Strong R, Lutz B, Marsicano G, Roberts JL, Giuffrida A.
Eur J Neurosci. 2009 Jun;29(11):2177-86. doi: 10.1111/j.1460-9568.2009.06764.x. Epub 2009 May 21.
PMID: 19490092 [PubMed – indexed for MEDLINE] Free PMC Article
Related citations
16. Cannabidiol: a promising drug for neurodegenerative disorders?
Iuvone T, Esposito G, De Filippis D, Scuderi C, Steardo L.
CNS Neurosci Ther. 2009 Winter;15(1):65-75. doi: 10.1111/j.1755-5949.2008.00065.x. Review.
PMID: 19228180 [PubMed – indexed for MEDLINE] Related citations
17. The endocannabinoid system as a target for the treatment of motor dysfunction.
Fernández-Ruiz J.
Br J Pharmacol. 2009 Apr;156(7):1029-40. doi: 10.1111/j.1476-5381.2008.00088.x. Epub 2009 Feb 13. Review.
PMID: 19220290 [PubMed – indexed for MEDLINE] Free PMC Article
Related citations
18. Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action.
Zuardi AW.
Rev Bras Psiquiatr. 2008 Sep;30(3):271-80. Review.
PMID: 18833429 [PubMed – indexed for MEDLINE] Free Article
Related citations
19. Cannabidiol for the treatment of psychosis in Parkinson’s disease.
Zuardi AW, Crippa JA, Hallak JE, Pinto JP, Chagas MH, Rodrigues GG, Dursun SM, Tumas V.
J Psychopharmacol. 2009 Nov;23(8):979-83. doi: 10.1177/0269881108096519. Epub 2008 Sep 18.
PMID: 18801821 [PubMed – indexed for MEDLINE] Related citations
20. The cannabinoid CP55,940 prolongs survival and improves locomotor activity in Drosophila melanogaster against paraquat: implications in Parkinson’s disease.
Jimenez-Del-Rio M, Daza-Restrepo A, Velez-Pardo C.
Neurosci Res. 2008 Aug;61(4):404-11. doi: 10.1016/j.neures.2008.04.011. Epub 2008 May 2.
PMID: 18538428 [PubMed – indexed for MEDLINE] Related citations

Allan Frankel, MD Dr Allan Frankel is one of the few physicians in the US who truly understands Cannabis as a medicine. All treatments suggested have been well studied. Every patient seen by Dr Frankel is given a personally created Treatment Plan created with the patient's specific issues defined. Plant medicine requires "tuning" of the dosing. Dr Frankel works with his patients thru a messaging portal. The use of this portal, allows quick and simple follow up contact with Dr Frankel. Patients are not charged for these messages, as this is how Dr Frankel has learned what he has learned. Follow up appointments in person or by phone/video are also available when needed

You Might Also Enjoy...

Rationing Health Care

With COVID, we have never been more aware of critical shortages of masks, ventilators, hospital beds, etc., all leading to rationing. In this BLOG, Dr Frankel, examines how rationing in our medical care is a much bigger problem than just face masks.

Cannabis May Prevent COVID-19 Infections

Early studies in both Israel and Canada show findings consistent with CBD's effect on COVID-19's ability to take hold in the lungs or the gastrointestinal tract. If the receptors are reduced, the viral infection and pulmonary toxicity should be reduced.